PROCESSA PHARMACEUTICALS INC (PCSA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.94-0.26%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PCSA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
PCSA — CEO transition
Dated 2026-11-04
COO — Gregory J. Flesher: The filing announces the appointment of an external candidate as Chief Operating Officer, which is a significant management addition but not a departure.
Why it matters: The July plan set a second-half 2027 target for food allergy data. A timely study start keeps that data window in reach.
Supportive ifA company filing or release says the food allergy Phase 2 study has begun. Enrollment is underway by the end of 2026.
Worry ifThe company reports no study start by December 31, 2026. Or it moves the planned data window past the second half of 2027.
Why it matters: The July plan called for the RMS study to start in the first half of 2027. A start on time supports the three-study plan.
Supportive ifA company filing or release confirms the RMS Phase 2 study starts by June 30, 2027.
Worry ifThe company reports the RMS study has not started by June 30, 2027, or moves its start past that date.
Why it matters: The new deal adds an oral FcRn drug program, but no study or data date is set. A named next step would show the work is moving forward.
Supportive ifProcessa names the first research milestone for the Generian program. This could mean choosing a lead candidate or starting a preclinical study.
Worry ifProcessa reports ending the Generian deal, or names no program step by the next annual update.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$284 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $1,076 loss on $10,000 · 10.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,439 loss on $10,000 · 84.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.